NSCLC Phase III Registration Program for First-Line Therapy

• Two Phase III studies of combination chemotherapy with and without Targretin® capsules

  • cisplatin / vinorelbine
  • carboplatin / paclitaxel

• Both studies to be randomized with approximately 600 patients each

• Survival as primary endpoint

• Program underway; completion 2003-2004

Previous slide

Next slide

Back to first slide

View graphic version